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Male breast cancer (MBC) is a rare disease and constitutes less than 1% of all breast carcinoma cases. Although MBC most often
presents with a palpable mass, failure to recognise the signiﬁcance of other symptoms may lead to a delay in diagnosis. Nipple
discharge (ND) is a rare symptom in men, but it may herald an underlying malignancy. We present two cases of (MBC) presenting
with ND and emphasise the importance of this clinical sign in suspecting underlying malignancy and an opportunity for early
diagnosis. We also discuss the clinical signiﬁcance of ND in men in relation to current literature.
1.Introduction
Male breast cancer (MBC) is a rare disease accounting for
less than 1% of all breast cancers [1, 2]. In central African
countries,thereisamuchhigherproportionofcasesofMBC
but the reasons for this geographical variation are unclear
[3, 4]. The incidence of both male and female breast cancer
seems to be rising [5]. While this trend may simply reﬂect
increasing life expectancy, it is likely that other explanations
exist. The average age at diagnosis of MBC is 68 years, which
is older than the typical presentation of female breast cancer
at mean age of 58 years. Furthermore, MBC has a unimodal
age distribution as opposed to female breast cancer which
has a bimodal peak at age 52 and 71 [2, 6–8]. This is not
necessarily due to a biological cause but is likely to be related
to the onset of breast screening in women at age 50.
Literature on MBC is limited due to its rarity, and
managementislargelybasedonevidencefromdataoffemale
breast cancer. However, MBC is not exactly the same as
female breast cancer [7, 8]. Although most cases present as
a palpable mass, it is imperative to be aware of other signs
and symptoms of MBC so that the disease may potentially
be detected at an earlier stage conferring a survival beneﬁt to
the patient [9]. One such sign of underlying MBC is nipple
discharge(ND).DataonNDinmeninthecurrentliterature,
however, is very limited. We present two cases of MBC
presenting with ND and discuss the clinical signiﬁcance of
this sign in men.
2.CaseReport
(1) A healthy 87-year-old man presented with a three-month
history of spontaneous, clear, left-sided ND. There was a
signiﬁcant family history of breast cancer as a maternal
aunt, and two sisters were diagnosed in their early 60’s. On
examination, he had a ﬁrm, 2cm mass in the upper outer
quadrant of the left breast. There was no skin ulceration or
tethering, no nipple retraction, and there were no enlarged
axillary lymph nodes. The discharge came from the centre of
the nipple, and, clinically, it was not possible to say if this
was uniductal. The discharge was sent for cytology, and a
core biopsy of the mass was also performed. ND cytology
was inconclusive with no evidence of any epithelial cells, but
core biopsy of the lump revealed the presence of invasive
adenocarcinoma.
After counselling, the patient went on to have a mas-
tectomy and axillary sentinel lymph node biopsy (SLNB).
Histology showed a grade 2 invasive papillary carcinoma
19mm in maximum dimension, with clear margins. No
lymphovascular invasion was seen, and the one SLNB
was negative for metastatic tumour. Immunohistochemistry
demonstrated the tumour was strongly oestrogen receptor2 Case Reports in Surgery
(ER) positive without HER2 over ampliﬁcation. The patient
made a good postoperative recovery and had adjuvant
endocrine treatment with tamoxifen. Due to his strong
family history, he was oﬀered genetic counselling but he
refused and remained well 2 years postoperatively.
(2) A 77-year-old gentleman presented with bloody ND
andalumpintheleftbreastfor6weeks.Therewasnohistory
of trauma and no family history of note. On examination,
there was a cord-like mass beneath the areola extending into
the upper outer quadrant of the left breast, with no skin or
nipple abnormality. The patient underwent a mammogram
and ultrasound scan both of which were highly suggestive
that the mass was malignant. The ND cytology revealed
atypical epithelial cells. Core biopsy of the mass revealed
the presence of invasive adenocarcinoma. The patient was
treated with mastectomy and SLNB. Histology revealed a
grade 2 invasive ductal carcinoma with clear margins and no
lymphovascularinvasionpresent.Asinglenodewasretrieved
at SLNB which was negative for metastatic carcinoma.
Immunohistochemistry showed the tumour was ER positive.
He was prescribed adjuvant tamoxifen and remained well 4
years postoperatively.
3. Discussion
MBC is often diagnosed at a later stage than in women
with more than 40% of men presenting with stage III or IV
disease [10]. Published series have also consistently reported
long median time intervals between onset of symptoms
and diagnosis of MBC [10, 11]. Prolonged duration of
symptomsandadvancedstageatpresentationisimportantas
it correlates with decreased survival [11]. Delays in diagnosis
of MBC are likely to result from a lack of awareness of
the risk of MBC and the signs and symptoms that may
indicate an underlying malignancy. Although the typical
presentation of MBC in 75% of patients is a painless, ﬁrm,
retroareolar breast lump, it is important to recognise the
other less obvious signs and symptoms of MBC including
nipple retraction, ulceration, Paget’s disease of the nipple,
axillary lymphadenopathy, breast pain, and ND [10–12].
NDaloneisanuncommonpresentingcomplaintinmen,
and published data is limited. Morrogh and King from the
Memorial Sloane Kettering Centre, New York, presents the
only signiﬁcant series of MBC patients presenting with ND
[13]. They found that among 430 patients who presented
to their institution with ND over a 10-year period only 3%
were male. However, 57% of these men presenting with
ND had an underlying malignancy. This is in contrast to
the female population in whom only 16% of patients who
presented with ND had an underlying malignancy. Other
smaller studies looking at the presence of ND in association
w i t hap a l p a b l em a s sh a v ef o u n dc a n c e rr a t e so fb e t w e e n1 5 –
75% [14, 15]. Therefore, although ND of the male breast is
uncommon, it warrants detailed evaluation due to its strong
association with underlying malignancy.
Morrogh and King also found a signiﬁcant delay in
presentationinmenwhopresentwithNDcomparedtothose
who present with a palpable mass. The median time interval
between onset of symptoms and diagnosis was 16 weeks for
patientspresentingwithNDand3weeksforthosepresenting
with a palpable mass, raising the possibility that had this
group recognised the signiﬁcance of the ND they may have
presented at an earlier stage [13].
For a male presenting with ND, the diagnostic pathway
followsthesameprinciplesforbreastcancerinwomenwhich
is based on triple assessment. Clinical suspicion of malig-
nancy is conﬁrmed by clinical examination. Approximately
half of men with a primary presenting complaint of ND have
an underlying palpable mass [13]. Additional investigations
suchasmammographyandtargetedultrasoundmayassistin
diagnosis. However, deﬁnitive diagnosis relies on pathologi-
cal assessment either with nipple ﬂuid cytology, ﬁne needle
aspiration cytology, or core biopsy of a mass.
The use of nipple ﬂuid cytology to distinguish between
patients with cancer and those with a benign ND has been
a subject of ongoing debate. Current data suggest that ND
cytological examination is only useful when positive and can
have a false-negative rate for cancer of up to 50% [16, 17].
In our two patients, both underwent ND cytology, with
cytology detecting suspicious malignant epithelial cells in
one of the two patients. Although there are case reports
describing the diagnosis of MBC on the basis of nipple
cytology alone [17], the overall clinical utility of this
investigation is questionable.
Although a high proportion of male patients presenting
with ND will have an underlying malignancy, approximately
43% have a benign cause for their ND [13]. A number
of benign causes for male ND have been described in the
literature [18–21]. Duct ectasia is benign dilatation and
shortening of the terminal ducts within 3cm of the nipple.
It is a common cause of ND in women increasing in
incidence with age but rare in the male breast. Tedeschi
and McCarthy reported the ﬁrst male case in 1974 since
when only a handful of cases have been reported in the
literature [22]. Recently, duct ectasia has been reported in
a man in association with the human immunodeﬁciency
virus infection and Bechet’s disease suggesting a possible
immune mechanism being responsible [21]. Papillomas are
characterised by formation of epithelial fronds that have
both a luminal epithelial and outer myoepithelial cell layers
supported by a ﬁbrovascular core. The epithelial component
can be subject to a spectrum of morphological changes
ranging from metaplasia to hyperplasia atypical intraductal
hyperplasia, and in situ carcinoma. Papillomas are again
common in the female population and the commonest cause
for bloody ND, but only a handful of cases occurring in men
have been reported in the literature [19]. Most recently, two
cases of intracystic papilloma causing ND in males on long-
termphenothiazinetreatmentforschizophreniaandelevated
p r o l a c t i nl e v e l sh a v eb e e nr e p o r t e d[ 20]. Other more rare
causes for benign ND in men include ﬁbrocystic change,
gynaecomastia, and various kinds of skin adnexal tumours
arising in breast tissue [18–23].
In conclusion, ND in men is rare but when present
carries a high probability of underlying malignancy. In
the absence of screening mammography, we rely on the
presence of clinical symptoms to detect MBC. Prognosis
is largely determined by the stage at diagnosis; thus, anyCase Reports in Surgery 3
delay in presentation or diagnosis may reduce survival. By
recognising subtle clinical features of early disease such as
ND, there may be a window of opportunity to improve
outcomes for male patients. An increased awareness of the
signiﬁcance of ND as an important symptom in men must
therefore be highlighted to physicians and patients alike.
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